ASCO 2024: Focus on Renal Cell Carcinoma
Dr. Zhang highlights the results of a phase 2 trial for sequential treatment of cabozantinib in advanced RCC.
The combination of SRS with IO significantly increases the OS in RCCBM compared with IO, WBRT, or WBRT plus IO.
KIM-1 levels were evaluated using a high-sensitivity electrochemiluminescence assay.
The KEYNOTE-426 study explored pembrolizumab and axitinib vs sunitinib in advanced RCC using genetic biomarkers.
Dr. Nguyen shares an ongoing study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma.
The trial previously demonstrated longer PFS rates with avelumab plus axitinib in patients with PD-L1-positive tumors.
New results of CheckMate 67T focused on additional safety analyses and patient-reported outcomes.
Patients who received lenvatinib plus pembrolizumab experienced later progression across tumors in multiple organs.
Patients with RCC who experience disease recurrence after adjuvant IO benefit from subsequent systemic therapies.
Investigators found that the median follow-up period was 16.5 months at the study’s cutoff date.
Dr. Doshi and colleagues designed an analysis of patients with metastatic ChRCC to better understand first-line therapy.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.